News from Tuesday, November 5, 2024
Articles
Mapping Health Care's Hidden Financial Burdens
(11/4, Maggie L. Shaw, The American Journal of Managed Care) reports “...The [Center for Innovation& Value Research] report notes that within patient-centered research, mapping can also be useful toward gaining a greater understanding of the natural history of the disease, identifying patient comparators (eg, different treatment options and their financial effects), and selecting outcomes to measure. Further, it can facilitate shifting the traditional perspective of journey mapping from health systems and payers to the patients and their caregivers and families, aggregate data, and bring much-needed attention to how complex the health care journey is for individuals living with serious health conditions.” Full
UK: NICE Backs First Ophthalmic Bevacizumab for NHS Use
(11/5, Phil Taylor, PharmaPhorum) reports “Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular degeneration (AMD). It is believed to be the first time that Lytenava (bevacizumab gamma) has been cleared for reimbursement in any European country...” Full
Journals
Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial
Xia Meng, MD; Shuya Li, MD; Hongguo Dai, MD; et al
September 12, 2024, JAMA
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower Costs
Katherine A. Clifford, et al.
November 2024, Health Affairs
The Role of Health Economics Within Health Technology Assessment: Past, Present, and Future - An Austrian Perspective
Ingrid Zechmeister-Koss, et al.
November 5, 2024, International Journal of Technology Assessment in Health Care